Grace Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Grace Therapeutics, Inc. (GRCE) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 12-month period ending 2022-03-31, per its 10-K filed 2022-06-21.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2022-06-21
- Grace Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2021-03-31 was $115.00K.
- Grace Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2020-12-31 was $81.00K.
- Grace Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Grace Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $196.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $0.00 derived: sum of 2 quarters · filed 2022-06-21 | $0.00 10-K · filed 2022-06-21 | |
| 2021-12-31 | $0.00 10-Q · filed 2022-02-14 | $0.00 10-Q · filed 2022-02-14 | ||
| 2021-03-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $196.00K derived: sum of 2 quarters · filed 2022-06-21 | $196.00K 10-K · filed 2022-06-21 | |
| 2020-12-31 | $81.00K 10-Q · filed 2022-02-14 | $81.00K 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |